Vaccine breakthrough and rebound infections modeling: Analysis for the United States and the ten U.S. HHS regions.

Olusegun Michael Otunuga, Alexandra Yu
Author Information
  1. Olusegun Michael Otunuga: Department of Mathematics, Augusta University, 1120 15th Str, GE 2018, Augusta, GA, 30912, USA.
  2. Alexandra Yu: Department of Mathematics, Augusta University, 1120 15th Str, GE 2018, Augusta, GA, 30912, USA.

Abstract

A vaccine breakthrough infection and a rebound infection cases of COVID-19 are studied and analyzed for the ten U.S. Department of Health and Human Services (HHS) regions and the United States as a nation in this work. An innovative multi-strain susceptible-vaccinated-exposed-asymptomatic-symptomatic-recovered () epidemic model is developed for this purpose for a population assumed to be susceptible to -different variants of the disease, and those who are vaccinated and recovered from a specific strain ( ≤ ) of the disease are immune to present strain and its predecessors  = 1, 2, …, , but can still be infected by newer emerging strains  =  + 1,  + 2, …, . The model is used to estimate epidemiological parameters, namely, the latent and infectious periods, the transmission rates, vaccination rates, recovery rates for each of the Delta B.1.617.2, Omicron B.1.1.529, and lineages BA.2, BA.2.12.1, BA.4, BA.5, BA.1.1, BA.4.6, and BA.5.2.6 for the United States and for each of the ten HHS regions. The transmission rate is estimated for both the asymptomatic and symptomatic cases. The effect of vaccines on each strain is analyzed. Condition that guarantees existence of an endemic with certain number of strains is derived and used to describe the endemic state of the population.

Keywords

References

  1. J Clin Virol. 2022 Dec;157:105299 [PMID: 36183546]
  2. Emerg Infect Dis. 2023 Mar;29(3):595-598 [PMID: 36787734]
  3. Int J Mol Sci. 2022 Jun 30;23(13): [PMID: 35806320]
  4. J Clin Med. 2021 Dec 23;11(1): [PMID: 35011781]
  5. Science. 2021 Apr 9;372(6538): [PMID: 33658326]
  6. Lancet Infect Dis. 2022 Dec;22(12):1666-1668 [PMID: 36328002]
  7. Lancet Microbe. 2023 Apr;4(4):e236-e246 [PMID: 36868258]
  8. PLoS One. 2020 Dec 9;15(12):e0243408 [PMID: 33296417]
  9. PLoS One. 2022 Jul 29;17(7):e0271446 [PMID: 35905113]
  10. Math Biosci Eng. 2022 Sep 8;19(12):13137-13151 [PMID: 36654039]
  11. Int J Surg. 2022 Mar;99:106261 [PMID: 35167986]
  12. Int J Infect Dis. 2020 May;94:145-147 [PMID: 32315808]
  13. J Travel Med. 2022 May 31;29(3): [PMID: 35262737]
  14. J Med Virol. 2022 May;94(5):1825-1832 [PMID: 35023191]
  15. J Med Virol. 2022 Oct;94(10):4780-4791 [PMID: 35680610]
  16. One Health. 2022 Dec;15:100425 [PMID: 35942477]
  17. PLoS One. 2021 Sep 16;16(9):e0257512 [PMID: 34529745]
  18. Nat Med. 2022 Sep;28(9):1785-1790 [PMID: 35760080]
  19. Lancet Infect Dis. 2022 Dec;22(12):1663-1665 [PMID: 36306800]
  20. Int J Infect Dis. 2023 Jan;126:132-135 [PMID: 36511336]
  21. Biomed Pharmacother. 2022 Oct;154:113522 [PMID: 36030585]
  22. J Theor Biol. 2022 Jul 21;545:111117 [PMID: 35513167]
  23. Results Phys. 2021 Sep;28:104664 [PMID: 34395184]
  24. Emerg Infect Dis. 2023 Mar;29(3):569-575 [PMID: 36737101]
  25. J Travel Med. 2022 Dec 27;29(8): [PMID: 36179096]
  26. Nonlinear Dyn. 2020;102(1):489-509 [PMID: 32921921]
  27. Math Biosci. 2018 Feb;296:82-92 [PMID: 29288702]
  28. Lancet Respir Med. 2022 Feb;10(2):e17 [PMID: 34929158]
  29. Results Phys. 2021 Feb;21:103772 [PMID: 33520629]
  30. Math Biosci. 2002 Nov-Dec;180:29-48 [PMID: 12387915]
  31. N Engl J Med. 2022 Nov 17;387(20):1904-1906 [PMID: 36260835]
  32. Infect Dis Poverty. 2022 Nov 26;11(1):115 [PMID: 36435792]

Word Cloud

Created with Highcharts 10.0.0BA12breakthroughinfectiontenHHSregionsUnitedStatesstrainratesreboundcasesanalyzedUSmodelpopulationdiseasestrainsusedtransmissionDeltaBOmicron456endemicVaccinevaccineCOVID-19studiedDepartmentHealthHumanServicesnationworkinnovativemulti-strainsusceptible-vaccinated-exposed-asymptomatic-symptomatic-recoveredepidemicdevelopedpurposeassumedsusceptible-differentvariantsvaccinatedrecoveredspecific ≤ immunepresentpredecessors = 1canstillinfectedneweremerging =  + 1 + 2estimateepidemiologicalparametersnamelylatentinfectiousperiodsvaccinationrecovery617529lineages12rateestimatedasymptomaticsymptomaticeffectvaccinesConditionguaranteesexistencecertainnumberderiveddescribestateinfectionsmodeling:AnalysisLineagesMulti-strainRebound

Similar Articles

Cited By